Neurology residents explore Parkinson's care, research advances and career opportunities at the 2026 MDS-PAS Movement Disorders School.

This small event features an interactive program with remarks on the state of Parkinson’s research and progress toward a cure. You’ll learn about our landmark Parkinson’s Progression Markers ...

Registration for the 2026 Parkinson’s Disease Therapeutics Conference is currently sold out. To stay up to date with the latest from the Foundation, sign up for our Researcher and Clinician Newsletter ...

Parkinson’s disease (PD) is different for everyone. How it affects your ability to work depends on the type and severity of your symptoms and the kind of work you do. Some people with Parkinson’s are ...

Years of work spent uncovering Parkinson’s secrets — defining the highly variable patient experience, shedding light on genetic origins of disease, mapping molecular pathways — are now paying off in a ...

For two decades, Team Fox members have turned their passions into progress for Parkinson’s research. In 2026, seven remarkable Team Fox fundraisers will reach the 10- or 15-year mark.

The Foundation leads a global consortium of over 2,000 researchers, facilitating scientific exchange and collaboration to accelerate preclinical research and better understand Parkinson’s disease ...

A DAF is your personal charitable savings account. You contribute money or assets now, and then recommend grants to causes you care about — including MJFF — whenever you’re ready. DAFs give you ...

Dr. Alastair Noyce is a Professor of Neurology and Neuroepidemiology at the Wolfson Institute of Population Health, Queen Mary University of London. He is a consultant neurologist at Barts Health NHS ...

Patrik Brundin joined the Van Andel Institute in 2012, where he is deputy chief scientific officer and directs the Parkinson’s Disease (PD) Center. He earned a PhD in 1988 and an MD in 1992 from Lund ...

This election season, California voters are considering Proposition 38, a ballot measure that would authorize $8.4 billion in state bonds for immunology and immunotherapy research at California ...

The U.S. Food and Drug Administration (FDA) has approved a new, long-acting oral formulation for the treatment of Parkinson's disease. Developed by Amneal Pharmaceuticals, Crexont aims to offer ...